ATE249239T1 - Medizinische verwendung des scupa/supar komplexes - Google Patents

Medizinische verwendung des scupa/supar komplexes

Info

Publication number
ATE249239T1
ATE249239T1 AT97946791T AT97946791T ATE249239T1 AT E249239 T1 ATE249239 T1 AT E249239T1 AT 97946791 T AT97946791 T AT 97946791T AT 97946791 T AT97946791 T AT 97946791T AT E249239 T1 ATE249239 T1 AT E249239T1
Authority
AT
Austria
Prior art keywords
scupa
supar
complex
plasminogen activator
formation
Prior art date
Application number
AT97946791T
Other languages
English (en)
Inventor
Abd Al-Rof Higazi
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Application granted granted Critical
Publication of ATE249239T1 publication Critical patent/ATE249239T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97946791T 1996-12-09 1997-12-09 Medizinische verwendung des scupa/supar komplexes ATE249239T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3267696P 1996-12-09 1996-12-09
PCT/IL1997/000402 WO1998025641A1 (en) 1996-12-09 1997-12-09 MEDICAL USES OF scuPA/suPAR COMPLEX

Publications (1)

Publication Number Publication Date
ATE249239T1 true ATE249239T1 (de) 2003-09-15

Family

ID=21866218

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946791T ATE249239T1 (de) 1996-12-09 1997-12-09 Medizinische verwendung des scupa/supar komplexes

Country Status (9)

Country Link
EP (1) EP0948342B1 (de)
JP (1) JP2001505907A (de)
AT (1) ATE249239T1 (de)
AU (1) AU735780B2 (de)
CA (1) CA2274477A1 (de)
DE (1) DE69724818T2 (de)
ES (1) ES2206752T3 (de)
IL (1) IL130336A0 (de)
WO (1) WO1998025641A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129332A (en) 1999-04-05 2006-12-10 Hadasit Med Res Service suPAR STIMULATING ACTIVITY OF tcuPA-MEDIATED FIBRINOLYSIS AND DIFFERENT USES THEREOF
US6759042B2 (en) * 1999-06-04 2004-07-06 Thrombotech Ltd Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
CN1188522C (zh) * 2001-07-20 2005-02-09 健力福生化技术（上海）有限公司 一种血栓靶向性溶栓蛋白表达质粒及其构建

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
WO1994018315A1 (en) * 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis

Also Published As

Publication number Publication date
WO1998025641A1 (en) 1998-06-18
IL130336A0 (en) 2000-06-01
ES2206752T3 (es) 2004-05-16
EP0948342B1 (de) 2003-09-10
EP0948342A4 (de) 2002-03-06
CA2274477A1 (en) 1998-06-18
EP0948342A1 (de) 1999-10-13
JP2001505907A (ja) 2001-05-08
AU5191398A (en) 1998-07-03
DE69724818D1 (de) 2003-10-16
AU735780B2 (en) 2001-07-12
DE69724818T2 (de) 2004-08-19

Similar Documents

Publication Publication Date Title
Manco-Johnson et al. Recommendations for tPA thrombolysis in children
Marder et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit
UA41398C2 (uk) Спосіб лікування пацієнта і спосіб зниження ризику кровотеч та крововиливів в мозок у хворого, який потребує тромболітичної терапії, фармацевтична комбінація у формі заздалегідь упакованої одиниці і фармацевтична пакувальна одиниця, що складається з цієї комбінації
Klement et al. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model
Zimmermann et al. Urokinase therapy of subclavian-axillary vein thrombosis
Vanderschueren et al. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis
Schulman et al. A comparative randomized trial of low-dose versus high-dose streptokinase in deep vein thrombosis of the thigh
ATE249239T1 (de) Medizinische verwendung des scupa/supar komplexes
Collen et al. Towards better thrombolytic therapy
Dewerchin et al. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase
WO2001097752A3 (en) Compositions comprising urokinase for modulating muscle contractility and angiogenisis
Bang Tissue-type plasminogen activator mutants. Theoretical and clinical considerations.
AU2003213856B2 (en) Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
US20060069035A1 (en) Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
Lerakis et al. New thrombolytics: What is under development?
US6911316B1 (en) Medical uses of scuPA/suPAR complex
US7271143B1 (en) Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
Wijngaards et al. Urokinase-related fibrinolytic activity in human plasma
Zimmermann et al. Urokinase therapy of deep vein thrombosis of the lower limb
Burke et al. Differential effects of Lys-and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model
Hirsh et al. Theoretical and practical aspects of thrombolytic therapy
IL129332A0 (en) suPAR STIMULATING ACTIVITY OF tcuPA-MEDIATED FIBRINOLYSIS AND DIFFERENT USES THEREOF
Zimmermann et al. Urokinase Treatment Of Phlegmasia Cerulea Dolens
Fenton II et al. Thrombin after clot formation
Müller et al. 160 Reperfusion of the carotid artery in rabbits: A new in vivo model of thrombolysis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties